Abstracts Archive - Page 2152 of 2425 - ACR Meeting Abstracts

Abstract Number: 1496 • 2013 ACR/ARHP Annual Meeting
DNA Methylation In Six Cell and Tissue Types In Sjögren’s Syndrome Reveals Distinct Patterns Across Samples and Clustering Based On Disease Status
Alice Baker¹, Diana Quach¹, Hong L. Quach¹, Emon Elboudwarej¹, Lisa F. Barcellos¹ and Lindsey A. Criswell², ¹Epidemiology, University of California, Berkeley, Berkeley, CA, ²Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA
Background/Purpose: Sjögren’s Syndrome (SS) is a chronic, multisystem autoimmune disease characterized by progressive destruction of the exocrine glands, with subsequent mucosal and conjunctival dryness. Increasing…
Abstract Number: 1497 • 2013 ACR/ARHP Annual Meeting
Endosomal TLR Triggering Of B Cells In Sjögren’s Syndrome Induces Increased Plasma Cells Differentiation, Ig Class Switch and Immunoglobulin Production
Marie Wahren-Herlenius¹, Susanna Brauner¹, Marika Kvarnström¹, Lasse Folkersen¹, Sabrina Görgen¹, Christina Trollmo², Vivianne Malmström³ and Gunnel Nordmark⁴, ¹Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Karolinska Institutet, Stochkolm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
Background/Purpose: Patients with primary Sjögren’s syndrome have B cell disturbances resulting in hypergammaglobulinemia and autoantibody production. Most patients are not treated by immunomodulatory drugs, enabling…
Abstract Number: 1498 • 2013 ACR/ARHP Annual Meeting
Hypofunction In Intact Cell Lobules Reflect Salivary Flow Rates In Sjogren’s Patients
Leyla Y Teos¹, Bill Swaim², Ana Paola Cotrim¹, Margaret Grisius³, Lolita Bebris⁴, Indu Ambudkar⁵, Gabor G. Illei⁶ and Ilias Alevizos⁷, ¹NIDCR, NIH, Bethesda, MD, ²Mptb, NIH/NIDCR, Bethesda, MD, ³NIH, Bethesda, MD, ⁴Sjogren's Clinic, NIDCR/NIH, Bethesda, MD, ⁵Molecular Physiology and Therapeutics Branch, NIDCR, Bethesda, MD, ⁶Clinical Development, MedImmune, LLC, Gaithersburg, MD, ⁷Sjogren's Clinic, NIDCR/ NIH #10 1N110, Bethesda, MD
Background/Purpose: Neurotransmitter stimulation of fluid secretion in salivary glands is regulated by increases in intracellular calcium concentration. The increase in cytosolic calcium triggers ion channel…
Abstract Number: 1499 • 2013 ACR/ARHP Annual Meeting
Detection Of CD4⁺CD25^lowGITR⁺ T Lymphocytes In Sjogren’s Syndrome-Interstitial Lung Disease
Wu Zhenbiao¹ and Chen Lina², ¹Clinical Immunology, First Affiliated Hospital, Fourth Military Medical University, Xi'An, China, ²Clinical Immunology, First Affiliated Hospital, Fourth Military Medical University, Xi‘an, China
Background/Purpose: CD4+CD25lowGITR+ T lymphocytes expressing FoxP3 and showing regulatory function have been recently described in healthy donors (HD). The objective of this study was to…
Abstract Number: 1458 • 2013 ACR/ARHP Annual Meeting
Rates Of Switching and Healthcare Costs Associated With Switching Biologic Disease-Modifying Antirheumatic Drugs In a Commercial Population: Evidence From Real-World Observational Studies
A Nadkarni, F Lobo and T Juday, Bristol-Myers Squibb, Plainsboro, NJ
Background/Purpose: Several biologic disease-modifying antirheumatic drugs (bDMARDs) are approved for the treatment of moderate-to-severe RA. Switching between bDMARD therapies is common in real-world settings, and…
Abstract Number: 1472 • 2013 ACR/ARHP Annual Meeting
Discontinuation Rates Of Tocilizumab Therapy In Rheumatoid Arthritis Patients In a Nonacademic Clinical Setting
Jaishree Manohar¹ and Charles H. Pritchard², ¹Rheumatology, Drexel University College of Medicine, Sarasota, FL, ²Rheumatology, Drexel University College of Medicine, Willow Grove, PA
Background/Purpose: Tocilizumab(TCZ) and other biologics are expensive and switching between them is difficult. The goal of this retrospective chart analysis is to identify the discontinuation…
Abstract Number: 1457 • 2013 ACR/ARHP Annual Meeting
Inhibitory Effect Of Abatacept On Joint Damage In Rheumatoid Arthritis Patients With Or Without Concomitant Methotrexate: A Retrospective Multicenter Analysis Of 12 Months Of Abatacept Treatment In Routine Clinical Practice
Isao Matsushita¹, Hiraku Motomura¹, Eiko Seki¹ and Tomoatsu Kimura², ¹Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan, ²Department of rthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan
Background/Purpose: Abatacept is approved for use with or without methotrexate (MTX). The purpose of this study was to clarify the inhibitory effect of abatacept on…
Abstract Number: 1459 • 2013 ACR/ARHP Annual Meeting
Multiple Cytokine Profiling Predicts The Effectiveness Of Switching Biologics In Rheumatoid Arthritis
Kensuke Koyama¹, Katsunori Ikari¹, Atsuo Taniguchi², Shigeki Momohara² and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: There is some rheumatoid arthritis (RA) patients with poor responses to certain biologics which requires switching to another biologics. However, there is no solid…
Abstract Number: 1460 • 2013 ACR/ARHP Annual Meeting
10 Years Of Treat-To-Target Therapy In Rheumatoid Arthritis Patients (the BeSt study): Clinical and Radiological Outcomes
I.M. Markusse¹, G. Akdemir¹, M. van den Broek¹, L. Dirven¹, R.J. Goekoop², K.H. Han³, M. van Oosterhout⁴, P.J.S.M. Kerstens⁵, W.F. Lems⁶, T.W.J. Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Haga Hospital, The Hague, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Long term studies with treat-to-target therapy are essential to guide treatment strategies. We report on a study that compared clinical and radiological outcomes of…
Abstract Number: 1461 • 2013 ACR/ARHP Annual Meeting
Corticosteroid Use In Rheumatoid Arthritis Patients On Infliximab: Treatment Implications Based On A REAL-WORLD Canadian Population
Boulos Haraoui¹, Algis V Jovaisas², William G. Bensen³, Rafat Y. Faraawi⁴, John T. Kelsall⁵, Sanjay Dixit⁶, Emmanouil Rampakakis⁷, John S. Sampalis⁷, Francois Nantel⁸, Susan M. Otawa⁹, Allen J. Lehman⁹ and May Shawi¹⁰, ¹Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁴Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, ⁵Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁶McMaster University, Hamilton, ON, Canada, ⁷JSS Medical Research, Montreal, QC, Canada, ⁸Janssen Inc., Toronto, ON, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
Abstract Number: 1462 • 2013 ACR/ARHP Annual Meeting
Unmasking The Tolerability Of Methotrexate In Patients With Rheumatoid and Psoriatic Arthritis: A Retrospective Review Of Discontinuation From a Large UK Cohort
Andra Negoescu¹, Elena Nikiphorou², Anshuman P. Malaviya³, Andrew Badcock³, John D. Fitzpatrick^3,4, Calum T. Goudie^3,4 and Andrew J. Ostor³, ¹Rheumatology, Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, ²Rheumatology, Addenbrooke's Hospital, Cambridge, United Kingdom, ³Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, ⁴University of Cambridge Medical School, Cambridge, United Kingdom
Background/Purpose: Due to its efficacy and perceived safety, methotrexate (MTX) has become the foundation disease-modifying drug for rheumatoid (RA) and psoriatic arthritis (PsA) however…
Abstract Number: 1463 • 2013 ACR/ARHP Annual Meeting
Dietary Impact On Treatment Results Of Methotrexate In Patients With Rheumatoid Arthritis
Cecilia Lourdudoss¹, Alicja Wolk², Camilla Bengtsson³, Lena Nise⁴, Lars Alfredsson³ and Ronald van Vollenhoven⁵, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Karolinska institutet, Stockholm, Sweden, ²Institute of Environmental Medicine (IMM), Karolinska institutet, Stockholm, Sweden, ³Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Institute of Environmental Medicine, Karolinska institutet, Stockholm, Sweden, ⁵Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose: Some specific diets have been shown to ameliorate rheumatoid arthritis (RA). However, there is generally a lack of studies on any possible dietary impact…
Abstract Number: 1464 • 2013 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcomes With Etanercept and Etanercept and Methotrexate In Patients With Rheumatoid Arthritis: Two-Year Results From The Canadian Methotrexate and Etanercept Outcome Study (CAMEO)
Boulos Haraoui¹, J. Carter Thorne², Edward C. Keystone³, Melanie Poulin-Costello⁴, Eric Trottier⁵, Andrew Vieira⁶ and Janet E. Pope⁷, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁴Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁵Medical Communications, Amgen Canada, Mississauga, ON, Canada, ⁶Amgen Canada Inc., Mississauga, ON, Canada, ⁷St Joseph Health Care, London, ON, Canada
Background/Purpose: Data from the CAMEO study demonstrated that patients with rheumatoid arthritis (RA) who achieved low disease activity (LDA) after 6 months of combination therapy…
Abstract Number: 1465 • 2013 ACR/ARHP Annual Meeting
Adherence To The Recommended Dosing Regimen Of Abatacept In The Real-World Setting In The Action Study: Is There a Dose-Creep In Overweight Patients?
H Nüßlein¹, R Alten², M Galeazzi³, H M Lorenz⁴, D Boumpas⁵, M T Nurmohamed⁶, W G Bensen⁷, Gerd Burmester⁸, H-H Peter⁹, F Rainer¹⁰, K Pavelka¹¹, M Chartier¹², C Poncet¹³, C Rauch¹⁴ and M Le Bars¹⁵, ¹University Erlangen, Nürnberg, Germany, ²Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital Heidelberg, Heidelberg, Germany, ⁵Panepistimio Kritis, Rethymnon, Greece, ⁶VU University Medical Center/Jan van Breeman Research Institute, Amsterdam, Netherlands, ⁷St. Joseph's Hospital/McMaster University, Hamilton, ON, Canada, ⁸Charité-Universitätsmedizin, Berlin, Germany, ⁹University of Freiburg, Freiburg, Germany, ¹⁰Hospital Barmherzige Brueder, Graz, Austria, ¹¹Institute of Rheumatology, Prague, Czech Republic, ¹²Chiltern International, Neuilly, France, ¹³Docs International, Nanterre, France, ¹⁴Bristol-Myers Squibb, Munich, Germany, ¹⁵Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: Reduced efficacy for achieving DAS28 30 kg/m2,1 which in theory could induce dose increases to maintain efficacy. Here we explore adherence to abatacept over…
Abstract Number: 1466 • 2013 ACR/ARHP Annual Meeting
Survival On Treatment Of The Second Line Biologic Therapy: Switch Or Swap Strategy?
Ennio G. Favalli¹, Martina Biggioggero², Antonio Marchesoni³ and Pier Luigi Meroni², ¹Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy, Milan, Italy, ²Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy, ³UOC Day Hospital Rheumatology, Gaetano Pini Institute, Milan, Italy, Milano, Italy
Background/Purpose: The strategy for the choice of the second biologic agent after the failure of the first TNF inhibitor is still an unclear aspect in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].